Clinical Trials · NCT07226765
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Amgen
- Enrollment
- 250
- Start date
- Nov 2025
- Locations
- 54 sites, 11 countries
- Primary endpoint
- Change in Apnea-hypopnea Index (AHI) from baseline at Week 52